In September 2017, a ground-breaking study was published in Nature Communication (Verhoef et al., 2017) presenting PseudoXa as a safe and effective reversal agent for prevention and treatment of bleeding in the presence of FXa-DOACs. The factor Xa from the venom of one of the most venomous snake in the world - the Australian brown snake named Pseudonaja textilis - was the source of inspiration for the creation PseudoXa. Venom factor Xa causes human blood to clot even in the presence of factor Xa inhibitors. Researchers of the LUMC identified the reason for this insensitivity and applied this to human factor Xa. The result was the engineered protein PseudoXa. PseudoXa is injected as an inactive pro-enzyme, and will immediately restoring hemostasis using natural pathways of blood coagulation. VarmX aims to place a best-in-class antidote on the market, with unrivalled safety profile, and effective half-life.
PseudoXa instantly restores hemostasis in patients with high concentrations of factor Xa inhibitors in their blood.